Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride Patent Expiration
Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride is Used for treating allergic rhinitis, respiratory allergies, nasal swelling, sinus congestion, and pressure in adults and children aged 12 and older. It was first introduced by Chattem Inc Dba Sanofi Consumer Healthcare
Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride Patents
Given below is the list of patents protecting Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Allegra-d 24 Hour Allergy And Congestion | US6613357 | Osmotic device containing pseudoephedrine and an H1 antagonist |
Dec 25, 2020
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion | US6039974 | Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
Jul 31, 2018
(Expired) | Chattem Sanofi |
| Allegra-d 24 Hour Allergy And Congestion | USRE39069 | Multi-layered osmotic device |
May 29, 2018
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion |
US6037353 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep 14, 2017
(Expired) | Chattem Sanofi |
| Allegra-d 24 Hour Allergy And Congestion |
US6037353 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep 14, 2017
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion | US6037353 | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar 14, 2017
(Expired) | Chattem Sanofi |
| Allegra-d 24 Hour Allergy And Congestion | US6037353 | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar 14, 2017
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion |
US5855912 (Pediatric) | Pharmaceutical compositions for piperidinalkanol compounds |
Aug 28, 2015
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion |
US6113942 (Pediatric) | Pharmaceutical composition for piperidinoalkanol compounds |
Aug 28, 2015
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion | US5855912 | Pharmaceutical compositions for piperidinalkanol compounds |
Feb 28, 2015
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion | US6113942 | Pharmaceutical composition for piperidinoalkanol compounds |
Feb 28, 2015
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion |
US7135571 (Pediatric) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov 18, 2014
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion |
US7138524 (Pediatric) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov 18, 2014
(Expired) | Chattem Sanofi |
| Allegra-d 24 Hour Allergy And Congestion |
US7138524 (Pediatric) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov 18, 2014
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion |
US5578610 (Pediatric) | Piperidine derivatives |
May 26, 2014
(Expired) | Chattem Sanofi |
| Allegra-d 24 Hour Allergy And Congestion |
US5578610 (Pediatric) | Piperidine derivatives |
May 26, 2014
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion | US7135571 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May 18, 2014
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion | US7138524 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May 18, 2014
(Expired) | Chattem Sanofi |
| Allegra-d 24 Hour Allergy And Congestion | US7138524 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May 18, 2014
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion | US5578610 | Piperidine derivatives |
Nov 26, 2013
(Expired) | Chattem Sanofi |
| Allegra-d 24 Hour Allergy And Congestion | US5578610 | Piperidine derivatives |
Nov 26, 2013
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion |
US6187791 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov 11, 2012
(Expired) | Chattem Sanofi |
| Allegra-d 12 Hour Allergy And Congestion |
US6399632 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov 11, 2012
(Expired) | Chattem Sanofi |
| Allegra-d 24 Hour Allergy And Congestion |
US6187791 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov 11, 2012
(Expired) | Chattem Sanofi |
| Allegra-d 24 Hour Allergy And Congestion |
US6399632 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov 11, 2012
(Expired) | Chattem Sanofi |
Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride. The first generic version for Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride was by Barr Laboratories Inc and was approved on Apr 14, 2005. And the latest generic version is by Dr Reddys Laboratories Ltd and was approved on May 31, 2022.
Given below is the list of companies who have filed for Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 1 generic for Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride. This 60mg;120mg version comes by the name FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG; 120MG | tablet, extended release | Over the counter | ORAL | N/A | Oct 30, 2017 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
| United States |
| |||||||||
2. BARR
Barr Laboratories Inc has filed for 1 generic for Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride. This 60mg;120mg version comes by the name FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Barr.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG; 120MG | tablet, extended release | Discontinued | ORAL | N/A | Apr 14, 2005 |
Manufacturing Plant Locations New
Barr's manufacturing plants are situated in 4 countries - Mexico, Singapore, United States, Philippines. Given below are the details of these plant locations as well as the firm names of Barr as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mexico |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Singapore |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| United States |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Philippines |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride. This 60mg;120mg version comes by the name FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG; 120MG | tablet, extended release | Over the counter | ORAL | N/A | May 31, 2022 |
4. DR REDDYS LABS LTD
Dr Reddys Laboratories Ltd has filed for 1 generic for Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride. This 180mg;240mg version comes by the name FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 180MG; 240MG | tablet, extended release | Over the counter | ORAL | N/A | Jun 22, 2011 |
5. IMPAX PHARMS
Impax Pharmaceuticals has filed for 1 generic for Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride. This 60mg;120mg version comes by the name FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Impax Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG; 120MG | tablet, extended release | Discontinued | ORAL | N/A | Nov 12, 2010 |
6. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 1 generic for Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride. This 60mg;120mg version comes by the name FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Sun Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG; 120MG | tablet, extended release | Over the counter | ORAL | N/A | Jan 29, 2015 |
Manufacturing Plant Locations New
Sun Pharm's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Sun Pharm as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||||||||||||
| India |
| |||||||||||||||||||||||||||||